Welcome to BDA

  "The future of molecular targeted therapy requires a detailed understanding of translational R&D and economics."


Navigation Home Navigation Navigation Publications Navigation News Navigation Events Navigation Links Navigation Contacts Navigation Information

    Sat 26 Jul 2014

Don't miss our
upcoming events

Brussels, 4-5 Oct. 2012
Preclinical/early clinical biomarker discovery

Vienna, 29 -30 Nov 2012
Present and future breast cancer management: bench to bedside and back

_______________________

Latest events

          Disclaimer

 
BDA Information
Click here to request information from BDA

Change text size

2009 Biotherapy Development Association




Professor Heinz Zwierzina

Professor  Heinz ZwierzinaProf. Heinz Zwierzina is the Chairman of the BDA. send email

He is currently Professor of Internal Medicine at Innsbruck University in Austria. His specialisation is in hematology and oncology.

He is an active member in many scientific research organisations and is sitting on numerous committees of international research bodies including the EORTC, National Cancer Institute (NCI), Cancer Research UK and European School of Oncology (ESO).

He has coordinated a grant of the European commission (BIOMED) " Organisation of preclinical and clinical research of anticancer therapy with biological response modifiers" and is a member of the European Commission-funded Euregenethy project "Harmonization of gene therapy throughout Europe".

He was the founder and previous chairman of the EORTC Biological Therapeutics Development Group which is composed of pre-clinical and clinical scientists.

In addition, he has published over 80 papers in peer-reviewed scientific journals and books, chaired/presented at numerous international meetings and is a member of the editorial board or reviewer for more than 15 international scientific journals.

Research Interest

He has extensive experience in early drug development with biological agents as well as the combination of biological agents with chemotherapy, eg. angiogenesis inhibitors therapeutic antibodies vaccines signal transduction inhibitors immunomodulators gene therapy One of his major interests in drug development is the definition and use of surrogate markers (eg proteomics, functional imaging etc.) in phase I/II cancer clinical trials in order to speed up and reduce the costs of the overall drug development programs.